NEW YORK (GenomeWeb News) - BioSeek said today it has entered into an agreement with the Belgian biopharmaceutical company UCB to evaluate drug compounds.
Under the agreement, BioSeek will use its BioMAP systems to support target differentiation, lead development, and drug-candidate selection activities for UCB compounds in several target classes. UCB is focused on developing therapeutics for central nervous system disorders, inflammation, and oncology.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.